Axis-Shield PoC - News and Events

News related to Axis-Shield PoC, products or tests can be found in the listed news below.

For a list of congresses or exhibitions the company is attending, please use the link on the right hand side.
For archived news, please use the link News Archive.

Axis-Shield interim results ended 30 June 2010

Dundee, Scotland, 25 August 2010. Axis-Shield plc (LSE:ASD, OSE:ASD), the international and innovative in vitro diagnostics company, today announces its interim results for the six months ended 30 June 2010. 25.08.2010

New BMJ paper supports use of CRP testing in General Practice

Dundee, Scotland, 15 May 2009: Axis-Shield plc (LSE:ASD, OSE:ASD), the international in-vitro diagnostics (IVD) company, today announces that the British Medical Journal (BMJ) has published results from Jochen Cals and colleagues, based in Maastricht University Medical Centre in the Netherlands, concerning a cluster-randomised, controlled clinical trial in the management of suspected lower respiratory tract infections in 20 Dutch general practices. 18.05.2009

Axis-Shield launches new Afinion website

Dundee, Scotland, 2 July 2009: Axis-Shield, the international in vitro diagnostics company, today announces the launch of a new website dedicated to its state-of-the-art Afinion Point of Care Analyser system at www.afinion.net. 02.07.2009

Axis-Shield streamlines & strengthens US sales & marketing for Afinion

Dundee, Scotland, 16 March, 2010: Axis-Shield (LSE:ASD, OSE:ASD), the international in vitro diagnostics (IVD) company, today announces that it has reached agreement with Abbott Diagnostics to repurchase full US marketing rights for its market-leading Afinion point-of-care analyser, as part of its previously announced commercialisation acceleration programme. 16.03.2010

Head of City Council Erling Lae opens new Axis-Shield PoC offices

Oslo, 19 June 2009. Erling Lae, head of Oslo’s City Council, opened Axis-Shield’s new building this week where offices and production are all under one roof. 19.06.2009

Afinion Performance Affirmed In New Publication

Dundee, Scotland, 18 March 2009: Axis-Shield plc (LSE:ASD, OSE:ASD), the international in-vitro diagnostics (IVD) company, today announces that a new paper has been published confirming the performance of its Afinion Point-of-Care System and the assay for HbA1c, used to monitor efficacy of blood glucose control in diabetes. 19.03.2009

NycoCard CRP test chosen for a large EU-study!

Oslo, Norway, 16 May 2008: Axis-Shield PoC is proud to announce that the point-of-care test for C-reactive protein, NycoCard CRP, has been chosen among other strong vendors of CRP tests, for the EU-funded HAPPY AUDIT project. The aim of the study is to reduce unnecessary prescription of antibiotics for respiratory tract infections in the primary care. 16.05.2008

Axis-Shield delivers sustained growth in 2009

Dundee, Scotland, 16 March, 2010: Axis-Shield plc (LSE:ASD, OSE:ASD), the international in vitro diagnostics (IVD) company based in Scotland and Norway, today announces its preliminary results for the year ended 31 December 2009. 17.03.2010

Afinion HbA1c quality tested by SKUP

SKUP (Scandinavian evaluation of laboratory equipment for primary health care), a collaboration between Scandinavian health professionals and authorities, has completed an evaluation of Afinion AS100 Analyzer and Afinion HbA1c. 14.05.2008

Axis-Shield receives United States FDA 510(K) clearance for Afinion Albumin/Creatinine ratio test

Dundee, Scotland, 18 February 2008: Axis-Shield (LSE:ASD, OSE:ASD) today announces that it has received Food and Drug Administration (FDA) 510(k) marketing clearance for its Albumin/Creatinine Ratio (ACR) test on the award-winning point-of-care Afinion™ system. The Afinion™ ACR test is CE-marked and currently available in Europe and the rest of the world, and will now be launched in the USA. The assay measures the ACR in urine and is a measure of kidney function and cardiovascular complications that may occur in people with poorly controlled diabetes. It complements the CLIA-waived Afinion™ HbA1c assay used for monitoring diabetes treatment in primary healthcare. 20.02.2008

Afinion Update

Dundee, Scotland, 8 January 2010: Axis-Shield plc (LSE:ASD, OSE:ASD), the international in-vitro diagnostics (IVD) company, today provides an update on the progress in 2009 of Afinion, its state-of-the-art, point-of-care analyser system, and announces a further acceleration of its commercialisation. 08.01.2010

Afinion HbA1c re-certified by NGSP

Oslo, 1 September 2009. Afinion HbA1c has successfully completed the National Glycohemoglobin Standardization Program (NGSP, USA) manufacturer certification. 02.09.2009

NycoCard HbA1c re-certified by NGSP

Oslo, 1 September 2009. NycoCard HbA1c has successfully completed the National Glycohemoglobin Standardization Program (NGSP, USA) manufacturer certification.read more

Axis-Shield Lipid Panel development for the Afinion system

Axis-Shield announces that it is developing a full lipid test panel for its award-winning Afinion Point-of-Care System, as an aid to cardiovascular risk assessment. The test panel will measure HDL and LDL-cholesterol and triglycerides, as well as total cholesterol and is expected to be launched in 2011-2012read more